In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk

ACP Journal Club3 October 2023In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wkDarren Lau, MD, PhDDarren Lau, MD, PhDUniversity of Alberta, Edmonton, Alberta, Canada (D.L.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/J23-0077 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationWharton S, Blevins T, Connery L, et al; GZGI investigators. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389:877-880. https://pubmed.ncbi.nlm.nih.gov/37351564Clinical Impact RatingsGIM/FP/GP: References1. Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022;399:259-269. [PMID: 34895470] Google Scholar2. Knop FK, Aroda VR, do Vale RD, et al; OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:705-719. [PMID: 37385278] Google Scholar3. Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216. [PMID: 35658024] Google Scholar Author, Article, and Disclosure InformationAuthors: Darren Lau, MD, PhDAffiliations: University of Alberta, Edmonton, Alberta, Canada (D.L.)Disclosures: The commentator has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J23-0077.This article was published at Annals.org on 3 October 2023.ACP Journal Club is editorially independent from Annals of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics October 2023Volume 176, Issue 10Page: JC116KeywordsAdverse eventsBody mass indexBody weightClinical trialsObesityOverweightSafetyTreatment guidelinesWeight loss ePublished: 3 October 2023 Issue Published: October 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...